Ahmet ELBAY, Cansu EKİNCİ, Rukiye ÇETİNKAYA, Hakan ÖZDEMİR, Ömer Faruk ÇALIM, Alper YENİGÜN

Kortikosteroid İçerikli Burun Spreyi Kullanımının Santral Seröz Koryoretinopati Gelişiminde Rolü Var mıdır?

Amaç: Bu çalışmanın amacı kortikosteroid içerikli burun spreyi kullanımının santral seröz koryoretinopati (SSR) gelişimine ve koroid ve retina pigment epiteli-Bruch membran kompleksi (RPE-BM) kalınlığı üzerine etkisini araştırmaktır.Gereç ve Yöntemler: Çalışmaya mometazon içerikli burun spreyi tedavisine başlanan 29 hasta (18 kadın, 11 erkek) dahil edildi. Hastaların ilaç kullanımından önce ve ilaç kullanmaya başladıktan bir hafta ve bir ay sonra sistolik kan basıncı (SKB), diyastolik kan basıncı (DKB), görme keskinliği, göz içi basıncı ile koroid ve RPE-BM kalınlıkları ölçüldü. Optik koherens tomografi kesitleri SSR gelişimi açısından incelendi. Ölçümler sağ gözden yapıldı.Bulgular: Tedavi sonrası hiçbir hastada SSR saptanmadı. Ortalama koroid kalınlığı ölçümlerinde başlangıç değerlerle kontrol muayenelerindeki ölçümler arasında istatistiksel olarak anlamlı değişiklikler saptanmadı: Temporal tarafta başlangıçta 292,48±73,02 µm, birinci haftada 296,83±79,09 µm, birinci ayda 295,41±74,13 µm (p=0,405); fovea altında başlangıçta 360,62±92,44 µm, birinci haftada 364,04±93,65 µm, birinci ayda 365,66±95,86 µm (p=0,208); nazal tarafta başlangıçta 282,86±96,11 µm, birinci haftada 285,28±93,25 µm, birinci ayda 284,28±98,14 µm (p=0,819); RPE-BM başlangıçta 21,65±2,86 µm iken birinci haftada 21,24±2,61 µm, birinci ayda ise 21,58±2,09 µm olarak ölçüldü. Farklılıklar istatistiksel olarak anlamlı değildi (p=0,450). Göz içi basıncı (p=0,450), SKB (p=0,257) ve DKB (p=0,249) ölçümlerinde de anlamlı fark saptanmadı.Tartışma ve Sonuç: Kortikosteroid kaynaklı SSR insidansını incelemek ve SSR gelişimi ile koroid ya da RPE-BM kalınlığı arasında bir ilişki olup olmadığını kesin olarak belirlemek için daha ileri çalışmalara ihtiyaç vardır

Does Corticosteroid Nasal Spray Use Play a Role in Development of Central Serous Chorioretinopathy?

Aim: In this study, we aimed to investigate effects of corticosteroid-containing nasal spray use on central serous chorioretinopathy (CSC) development and thickness of choroid and retinal pigment epithelium–Bruch membrane complex (RPE-BM). Materials and Methods: Twenty-nine patients (18 female, 11 male) receiving nasal mometasone spray treatment were included in the study. Systolic blood pressure (SBP), diastolic blood pressure (DBP), visual acuity, intraocular pressure and choroidal and RPE-BM thickness were measured before and one week and one month after the medication. Optical coherence tomography sections were examined for CSC development. The measurements were made from the right eye.Results: Central serous chorioretinopathy was not detected in any of the patients. Mean choroidal thickness values did not show any statistically significant changes between the initial and follow-up measurements: On the temporal side 292.48±73.02 μm in beginning, 296.83±79.09 μm one week after, 295.41±74.13 μm one month after (p=0.405); under the fovea 360.62±92.44 μm in beginning, 364.04±93.65 μm one week after, 365.66±95.86 μm one month after (p=0.208); on the nasal side 282.86±96.11 μm in beginning, 285.28±93.25 μm one week after, 284.28±98.14 μm one month after (p=0.819); and RPE-BM 21.65±2.86 μm in beginning, 21.24±2.61 μm one week after, 21.58±2.09 μm one month after. Differences were not statistically significant (p=0.450). There was no significant difference in intraocular pressure (p=0.450), SBP (p=0.257) and DBP (p=0.249) measurements.Discussion and Conclusion: Further studies are needed to determine the incidence of corticosteroid-induced CSC and the cause–effect relationship between CSC development and choroid or RPE-BM thickness

PDF

___

1. Von Graefe A. Ueber centrale recidivierende Retinitis. Graefes Arch Clin Exp Ophthalmol. 1866;12:211–5.
2. Nicholson B, Noble J, Forooghian F, Meyerle C. Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol. 2013;58(2):103–26.
3. Bouzas EA, Karadimas P, Pournaras CJ. Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol. 2002;47(5):431–48.
4. Mirza RG, Gill M. Central serous chorioretinopathy associated with unusual routes of steroid administration. Retinal Cases Brief Rep. 2009;3(1):99–101.
5. Yannuzzi LA. Central serous chorioretinopathy: a personal perspective. Am J Ophthalmol. 2010;149(3):361–3
6. Imamura Y, Fujiwara T, Margolis R, Spaide RF. Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina. 2009;29(10):1469–73
7. Sibayan SA, Kobuch K, Spiegel D, Eckert E, Leser R, Monzer J ve ark. Epinephrine, but not dexamethasone, induces apoptosis in retinal pigment epithelium cells in vitro: possible implications on the pathogenesis of central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2000;238(6):515–9.
8. Kerscher MJ, Hart H, Korting HC, Stalleicken D. In vivo assessment of the atrophogenic potency of mometasone furoate: a newly developed chlorinated potent topical glucocorticoid as compared to other topical glucocorticoids old and new. Int J Clin Pharmacol Ther. 1995;33(4):187–9.
9. Wishart JM, Lee IS. Mometasone versus betamethasone creams: a trial in dermatoses. N Z Med J. 1993;106(256):203–5.
10. Samson C, Peets E, Winter-Sperry R, Wolkoff H. Mometasone furoate -Elocon- A medium potency topical corticosteroid with favorable efficacy / safety profile. In: Maibach HI, Surber C (ed.), Topical Corticosteroids. Basel: Karger AG; 1992:462–79.
11. Berkowitz RB, Bernstein DI, Laforce C, Pedinoff AJ, Rooklin AR, Damaraju CR ve ark. Onset of action of mometasone furoate nasal spray (NASONEX) in seasonal allergic rhinitis. Allergy. 1999;54(1):64–9.
12. Jain IS, Singh K. Maculopathy a corticosteroid side-effect. J All India Ophthalmol Soc. 1966;14(6):250–2.
13. Gass JDM. Stereoscopic Atlas of Macular Diseases: Diagnosis and Treatment, 2. ed. St Louis: CV Mosby; 1977:28–41.
14. Harada T, Harada K: Six cases of central serous choroidopathy induced by systemic corticosteroid therapy. Doc Ophthalmol. 1985;60(1):37–44.
15. Fernandez CF, Mendoza AJ, Arevalo JF. Central serous chorioretinopathy associated with topical dermal corticosteroids. Retina. 2004;24(3):471–4.
16. Ricketti PA, Unkle DW, Cleri DJ, Prenner JL, Coluccielo M, Ricketti AJ. Central serous chorioretinopathy secondary to corticosteroids in patients with atopic disease. Allergy Asthma Proc. 2015;36(2):123–9.
17. Haimovici R, Gragoudas ES, Duker JS, Sjaarda RN, Eliott D. Central serous chorioretinopathy associated with inhaled or intranasal corticosteroids. Ophthalmology. 1997;104(10):1653–60.
18. Kleinberger AJ, Patel C, Lieberman RM, Malkin BD. Bilateral central serous chorioretinopathy caused by intranasal corticosteroids: a case report and review of the literature. Laryngoscope. 2011;121(9):2034–7.
19. Tuncay FY, Gürelik G. Santral seröz koryoretinopati. Ret-Vit. 2010;18(2):85–111.
20. Pryds A, Larsen M. Choroidal thickness following extrafoveal photodynamic treatment with verteporfin in patients with central serous chorioretinopathy. Acta Ophthalmol. 2012;90(8):738–43.
21. Jirarattanasopa P, Ooto S, Tsujikawa A, Yamashiro K, Hangai M, Hirata M ve ark. Assessment of macular choroidal thickness by optical coherence tomography and angiographic changes in central serous chorioretinopathy. Ophthalmology. 2012;119(8):1666–78.
22. Yenigun A, Elbay A, Dogan R, Ozturan O, Ozdemir MH. The effect of allergic rhinitis with positive skin prick test on choroidal thickness. Eur Arch Otorhinolaryngol. 2017;274(6):2477–81.
23. Han JM, Hwang JM, Kim JS, Park KH, Woo SJ. Changes in choroidal thickness after systemic administration of high-dose corticosteroids: a pilot study effect of corticosteroids on choroidal thickness. Invest Ophthalmol Vis Sci. 2014;55(1):440–5.
24. Wakakura M, Song E, Ishikawa S. Corticosteroid-induced central serous chorioretinopathy. Jpn J Ophthalmology. 1997;41:180–85.
25. Wakakura M, Ishikawa S. Central serous chorioretinopathy complicating systemic corticosteroid treatment. British J Ophthalmol. 1984;68(5):329–31.
26. Tittl MK, Spaide RF, Wong D, Pilotto E, Yannuzzi LA, Fisher YL ve ark. Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol. 1999;128(1):63–8.
27. Dodic M, Wintour EM, Coghlan J. Effect of steroid hormones on blood pressure. Clin Exp Pharmacol Physiol. 1999;26(7):550–2.
28. Tittl M, Maar N, Polska E, Weigert G, Stur M, Schmetterer L. Choroidal hemodynamic changes during isometric exercise in patients with inactive central serous chorioretinopathy. Invest Ophthalmol Vis Sci. 2005;46(12):4717– 21.
29. Tan CS, Ouyang Y, Ruiz H, Sadda SR. Diurnal variation of choroidal thickness in normal, healthy subjects measured by spectral domain optical coherence tomography. Invest Ophthalmol Vis Sci. 2012;53(1):261–6.
30. Ulaş F, Doğan Ü, Keleş A, Ertilav M, Tekçe H, Çelebi S. Evaluation of choroidal and retinal thickness measurements using optical coherence tomography in non-diabetic haemodialysis patients. Int Ophthalmol. 2013;33(5):533–9.